Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma

Authors: Tianxiang Chen, Dongli Song, Zhihui Min, Xiangdong Wang, Yu Gu, Bajin Wei, Jia Yao, Kangjie Chen, Zhijun Jiang, Haiyang Xie, Lin Zhou, Shusen Zheng

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

Intratumoral and circulating regulatory T cells (Tregs) have been shown to be critical in the pathogenesis of hepatocellular carcinoma (HCC). However there is limited knowledge on the alterations of regulatory B cells (Bregs). We here investigated perioperative dynamic alterations of peripheral circulating Tregs and Bregs in HCC patients to reveal the relationship between regulatory lymphocytes and its clinical implications.

Methods

36 patients with HCC, 6 with chronic hepatitis B infection and 10 healthy donors were enrolled for this study. Frequencies of peripheral Tregs and Bregs were measured by flow cytometry with antibodies against CD4, CD25, CD127, CD19 and IL-10 before, and after radical surgery. Then, clinical informatics of HCC patients was achieved through Digital Evaluation Score System (DESS) for the assessment of disease severity. Finally, we analysed correlations between digitalized clinical features and kinetics of circulating regulatory lymphocytes.

Results

Level of circulating CD4+CD25+CD127- Tregs in HCC patients was significantly lower than that in healthy donors and patients with chronic hepatitis B infection before surgery, but was increased after surgery. Preoperative level of CD19+ IL-10+ Bregs in HCC patients was also significantly lower than the other groups. However it dramatically was elevated right after surgery and remained elevated compared to controls (about 7 days after surgery, P = 0.04). Frequency of circulating Tregs was correlated with circulating leukocytes, ferritin, and clinical features suggesting tumor aggressiveness including portal vein thrombosis, hepatic vein involvement and advanced clinical stages. Frequency of circulating Bregs was associated with Hepatitis B e Antigen (HBeAg) and Hepatitis B virus (HBV) DNA copy number. In addition, DESS was significantly and positively correlated with other staging systems.

Conclusion

Frequencies of peripheral Tregs and Bregs in HCC patients increased after surgery. These results suggest that a postoperative combination of therapies against Tregs and Bregs may be beneficial for better outcome of HCC patients after resection.
Appendix
Available only for authorised users
Literature
1.
Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 2010, 127: 759-767.PubMed
2.
3.
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007, 25: 2586-2593. 10.1200/JCO.2006.09.4565.CrossRefPubMed
4.
Chen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS: Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol. 2011
5.
Lee WC, Wu TJ, Chou HS, Yu MC, Hsu PY, Hsu HY, Wang CC: The impact of CD4(+)CD25(+) T cells in the tumor microenvironment of hepatocellular carcinoma. Surgery. 2011
6.
Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65: 2457-2464. 10.1158/0008-5472.CAN-04-3232.CrossRefPubMed
7.
Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y: Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 2006, 45: 254-262. 10.1016/j.jhep.2006.01.036.CrossRefPubMed
8.
Mauri C, Blair PA: Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol. 2010, 6: 636-643. 10.1038/nrrheum.2010.140.CrossRefPubMed
9.
Inoue S, Leitner WW, Golding B, Scott D: Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006, 66: 7741-7747. 10.1158/0008-5472.CAN-05-3766.CrossRefPubMed
10.
Mauri C, Ehrenstein MR: The 'short' history of regulatory B cells. Trends Immunol. 2008, 29: 34-40. 10.1016/j.it.2007.10.004.CrossRefPubMed
11.
12.
Vitale G, Mion F, Pucillo C: Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol. 2010, 48: 1-8. 10.1016/j.molimm.2010.09.010.CrossRefPubMed
13.
Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF: Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008, 118: 3420-3430.PubMedPubMedCentral
14.
Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M: Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010, 184: 4801-4809. 10.4049/jimmunol.0902385.CrossRefPubMedPubMedCentral
15.
Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder TF, Sato S: IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol. 2011, 178: 735-743. 10.1016/j.ajpath.2010.10.022.CrossRefPubMedPubMedCentral
16.
Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res. 2011, 71: 3505-3515. 10.1158/0008-5472.CAN-10-4316.CrossRefPubMedPubMedCentral
17.
DiLillo DJ, Matsushita T, Tedder TF: B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010, 1183: 38-57. 10.1111/j.1749-6632.2009.05137.x.CrossRefPubMed
18.
Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR: B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA. 2011, 108: 10662-10667. 10.1073/pnas.1100994108.CrossRefPubMedPubMedCentral
19.
Chen H, Song Z, Qian M, Bai C, Wang X: Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study. J Cell Mol Med. 2011
20.
Ganem D, Prince AM: Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004, 350: 1118-1129. 10.1056/NEJMra031087.CrossRefPubMed
21.
Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH: Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011
22.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983, 220: 868-871. 10.1126/science.6189183.CrossRefPubMed
23.
Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ: Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods. 2007, 322: 57-69. 10.1016/j.jim.2007.02.003.CrossRefPubMedPubMedCentral
24.
Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, Gibot S: The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care. 2010, 14: R19-10.1186/cc8876.CrossRefPubMedPubMedCentral
25.
Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, Damoiseaux J: Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol. 2011
26.
Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011, 117: 530-541. 10.1182/blood-2010-07-294249.CrossRefPubMedPubMedCentral
27.
Kawaoka T, Aikata H, Takaki S, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Kamada K, Kitamoto M: Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. Hepatol Res. 2010, 40: 1082-1091. 10.1111/j.1872-034X.2010.00714.x.CrossRefPubMed
28.
Yuen MF, Chan AO, Wong BC, Hui CK, Ooi GC, Tso WK, Yuan HJ, Wong DK, Lai CL: Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol. 2003, 98: 1181-1185.PubMed
29.
Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S: Hepatic Resection for "BCLC Stage A" Hepatocellular Carcinoma. The Prognostic Role of Alpha-Fetoprotein. Ann Surg Oncol. 2011
30.
Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003, 38: 207-215. 10.1007/s005350300038.CrossRefPubMed
31.
Zabala M, Lasarte JJ, Perret C, Sola J, Berraondo P, Alfaro M, Larrea E, Prieto J, Kramer MG: Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol. 2007, 47: 807-815. 10.1016/j.jhep.2007.07.025.CrossRefPubMed
32.
Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P: Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol. 2010, 184: 5885-5894. 10.4049/jimmunol.0903143.CrossRefPubMed
33.
Xiong B, Feng G, Luo S, Liang H, Qiu L, Zheng C, Liu X, Zhou G: Changes of CD4(+) CD25 (+) regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE. J Huazhong Univ Sci Technolog Med Sci. 2008, 28: 645-648. 10.1007/s11596-008-0606-7.CrossRefPubMed
34.
Feng X, Li B, Ye H, Long D: Increased frequency of CD4+CD25(high)FoxP3+ regulatory T cells in patients with hepatocellular carcinoma. Arch Immunol Ther Exp (Warsz). 2011, 59: 309-314. 10.1007/s00005-011-0127-0.CrossRef
35.
Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St, Groth B: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006, 203: 1701-1711. 10.1084/jem.20060772.CrossRefPubMedPubMedCentral
36.
Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed
37.
Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, Zheng SS: Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis. PLoS One. 2011, 6: e24671-10.1371/journal.pone.0024671.CrossRefPubMedPubMedCentral
38.
Wang Y, Wang W, Wang L, Wang X, Xia J: Regulatory mechanisms of interleukin 8 production induced by tumor necrosis factor-alpha in human hepatocellular carcinoma cells. J Cell Mol Med. 2011
39.
Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK: Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002, 16: 219-230. 10.1016/S1074-7613(02)00274-1.CrossRefPubMed
40.
Matsushita T, Horikawa M, Iwata Y, Tedder TF: Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol. 2010, 185: 2240-2252. 10.4049/jimmunol.1001307.CrossRefPubMedPubMedCentral
41.
Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C: Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011, 186: 5569-5579. 10.4049/jimmunol.1100284.CrossRefPubMed
42.
Geng L, Deng J, Jiang G, Song P, Wang Z, Jiang Z, Zhang M, Zheng S: B7-H1 up-regulated expression in human hepatocellular carcinoma tissue: correlation with tumor interleukin-10 levels. Hepatogastroenterology. 2011, 58: 960-964.PubMed
43.
Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L, Chen HS: Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Int J Oncol. 2010, 36: 841-848.PubMed
44.
Bahlo DSaA: B Lymphocytes in Cancer Immunology. Experimental and Applied Immunotherapy. 2011, Part 2: 37-57.
45.
Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K: The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood. 2011, 117: 4826-4835. 10.1182/blood-2010-12-324038.CrossRefPubMed
46.
Gray CP, Franco AV, Arosio P, Hersey P: Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int J Cancer. 2001, 92: 843-850. 10.1002/ijc.1269.CrossRefPubMed
47.
Baumgartner C, Osl M, Netzer M, Baumgartner D: Bioinformatic-driven search for metabolic biomarkers in disease. J Clin Bioinforma. 2011, 1: 2-10.1186/2043-9113-1-2.CrossRefPubMedPubMedCentral
48.
49.
Metadata
Title
Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma
Authors
Tianxiang Chen
Dongli Song
Zhihui Min
Xiangdong Wang
Yu Gu
Bajin Wei
Jia Yao
Kangjie Chen
Zhijun Jiang
Haiyang Xie
Lin Zhou
Shusen Zheng
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-14

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue

Review

Standards and pitfalls of focal ischemia models in spontaneously hypertensive rats: With a systematic review of recent articles

Research

Expression of chemokine receptors on circulating tumor cells in patients with solid tumors

Research

Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats

Review

TGF-β – an excellent servant but a bad master

Research

Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA

Research

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits